ArticleCancer2026
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis clinical trial sought to determine whether SL-172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher-risk myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML).
methodsDose escalation: doses of 1, 3, and 6 mg/kg SL-172154 was evaluated as monotherapy or in combination with AZA in patients with relapsed, refractory HR-MDS or AML. Expansion: a SL-172154 dose that could be safely combined with AZA was evaluated in patients with previously untreated HR-MDS or TP53 mutant (TP53m) AML.
objectivessafety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.
resultsEighty-one patients with HR-MDS (n = 33) or AML (n = 48) were enrolled in dose escalation (n = 37) or expansion (n = 44). Infusion-related reaction was the most common SL-172154-related toxicity and led to a dose limiting toxicity at 6 mg/kg. A dose of 3 mg/kg SL-172154 plus AZA was evaluated in patients with previously untreated HR-MDS (n = 21 with TP53m and n = 3 with TP53 wild type) and AML (n = 21 with TP53m). CD47 and CD40 engagement by SL-172154 was detected on leukemic blasts, myeloid, and lymphoid cells. Complete remission (CR) was achieved in 10 of 24 (43%) HR-MDS and six of 21 (29%) TP53m AML patients with median overall survival (OS) of 11.0 months (95% CI, 5.0-15.6) and 11.7 months (95% CI, 1.97-NE), respectively. Of patients in a CR, six of 10 HR-MDS and three of six TP53m AML patients achieved complete cytogenetic CR.
conclusionsSL-172154 plus AZA was generally well tolerated with favorable CR rates in pts with TP53m HR-MDS or AML, although without substantial improvement in OS when compared to historical benchmarks for AZA or AZA/VEN, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.